Editas Medicine, Inc. Common Stock (EDIT) — Analysis Summary
Editas Medicine, Inc. Common Stock (EDIT) has a market cap of $485.31M with year-over-year revenue growth of +25.4%. Net margin stands at -395.0%. The stock trades at a P/E ratio of -6.6.
Key Takeaways
- Revenue changed +25.4% year-over-year
- Net margin of -395.0%
- P/E ratio of -6.6
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, EDIT posted revenue growth of +25.4% and trades at a P/E of -6.6.
Editas Medicine, Inc. Common Stock (EDIT)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -26.2x — earnings do not cover interest payments
Operating margin at -161.4% — severe operating losses
Net margin at -157.3% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
87
Headquarters
CAMBRIDGE, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.